Nuo Therapeutics Files 8-K: Material Agreement & Financials
Ticker: AURX · Form: 8-K · Filed: May 21, 2024 · CIK: 1091596
| Field | Detail |
|---|---|
| Company | Nuo Therapeutics, Inc. (AURX) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $0.75, $650,875, $101,250, $11,250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, equity-securities
TL;DR
Nuo Therapeutics filed an 8-K detailing a material definitive agreement and financial updates.
AI Summary
On May 17, 2024, Nuo Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing details relate to Nuo Therapeutics, Inc.'s operations and financial reporting.
Why It Matters
This 8-K filing provides crucial updates on Nuo Therapeutics' material agreements and financial status, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, necessitating careful review by investors.
Key Numbers
- 000-28443 — SEC File Number (Nuo Therapeutics' SEC filing identifier)
- 23-3011702 — IRS Employer Identification No. (Nuo Therapeutics' tax identification number)
Key Players & Entities
- Nuo Therapeutics, Inc. (company) — Registrant
- May 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 8285 El Rio, Suite 190, Houston, Texas 77054 (address) — Company Address
FAQ
What type of material definitive agreement did Nuo Therapeutics, Inc. enter into?
The filing states that Nuo Therapeutics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.
What is the significance of the 'Unregistered Sales of Equity Securities' mentioned in the filing?
This indicates that the company may have issued equity securities without registering them with the SEC, which could have implications for dilution and regulatory compliance.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 17, 2024.
What is Nuo Therapeutics, Inc.'s state of incorporation?
Nuo Therapeutics, Inc. is incorporated in Delaware.
Where is Nuo Therapeutics, Inc. located?
Nuo Therapeutics, Inc. is located at 8285 El Rio, Suite 190, Houston, Texas 77054.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-21 08:30:13
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock") at a pri
- $0.75 — hare (the "Common Stock") at a price of $0.75 per share for gross proceeds of $650,87
- $650,875 — f $0.75 per share for gross proceeds of $650,875 (the "Private Placement"). The closing
- $101,250 — . Pittman, Clausen, and Sheedy invested $101,250, $11,250, and $75,000, respectively, in
- $11,250 — Clausen, and Sheedy invested $101,250, $11,250, and $75,000, respectively, in the Priv
- $75,000 — Sheedy invested $101,250, $11,250, and $75,000, respectively, in the Private Placement
Filing Documents
- aurx20240514_8k.htm (8-K) — 23KB
- ex_674354.htm (EX-10.1) — 103KB
- 0001437749-24-017754.txt ( ) — 271KB
- noticker-20240517.xsd (EX-101.SCH) — 3KB
- noticker-20240517_def.xml (EX-101.DEF) — 10KB
- noticker-20240517_lab.xml (EX-101.LAB) — 14KB
- noticker-20240517_pre.xml (EX-101.PRE) — 10KB
- aurx20240514_8k_htm.xml (XML) — 2KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On May 17, 2024, Nuo Therapeutics, Inc. (the "Company") entered into a Securities Purchase Agreement, dated as of May 10, 2024, with certain accredited investors for the sale of 867,833 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") at a price of $0.75 per share for gross proceeds of $650,875 (the "Private Placement"). The closing of the Private Placement occurred on May 20, 2024. The investors in the Private Placement included Scott M. Pittman, a member of the Board of Directors of the Company, Peter A. Clausen, the Chief Scientific and Chief Operating Officer of the Company, and Charles E. Sheedy, a principal stockholder of the Company of the Company. Messrs. Pittman, Clausen, and Sheedy invested $101,250, $11,250, and $75,000, respectively, in the Private Placement. The proceeds of the Private Placement will be used for working capital purposes. As a result of the Private Placement, the number of shares of Common Stock outstanding is 45,109,349. The description of the Securities Purchase Agreement is qualified in its entirety by reference to the full text of such agreement filed as Exhibits 10.1 hereto.
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. The disclosure required by this Item as included in Item 1.01 of this report is incorporated herein by reference. The shares of Common Stock were offered and sold pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 thereunder, in a transaction not involving any public offering.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Chief Financial Officer Date: May 21, 2024